Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia

BACKGROUND: An individualised risk-stratified screening for prostate cancer (PCa) would select the patients who will benefit from further investigations as well as therapy. Current detection methods suffer from low sensitivity and specificity, especially for separating PCa from benign prostatic cond...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Cancer
Autori principali: Giskeødegård, Guro F, Hansen, Ailin Falkmo, Bertilsson, Helena, Gonzalez, Susana Villa, Kristiansen, Kåre Andre, Bruheim, Per, Mjøs, Svein A, Angelsen, Anders, Bathen, Tone Frost, Tessem, May-Britt
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2015
Soggetti:
Molecular Diagnostics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4702000/
https://ncbi.nlm.nih.gov/pubmed/26633561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.411
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi